A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment interleukin 6 and clinical stage

Copyright © 2016 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 164(2016) vom: 25. März, Seite 45-51
Auteur principal: Ke, Liangru (Auteur)
Autres auteurs: Xiang, Yanqun, Xia, Weixiong, Yang, Jing, Yu, Yahui, Ye, Yanfang, Liang, Hu, Guo, Xiang, Lv, Xing
Format: Article en ligne
Langue:English
Publié: 2016
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't Distant metastasis Interleukin-6 Nasopharyngeal carcinoma Prognostic model Survival IL6 protein, human
Description
Résumé:Copyright © 2016 Elsevier Inc. All rights reserved.
Because inflammation plays a critical role in nasopharyngeal carcinoma (NPC), this study aims to investigate the correlation between the pro-inflammation cytokine interleukin-6 (IL6) and the prognosis of NPC and develop a new prognostic model. IL6 levels were measured in the serum of 290 NPC patients by ELISA and the correlation between IL6 and prognosis of NPC was evaluated by Kaplan-Meier analysis and multivariate analysis. The results showed that elevated IL6 levels were positively correlated with poorer 9-year overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS) and lung metastasis-free survival (lung-MFS). IL6 level was an independent prognostic factor for OS, DFS, DMFS and lung-MFS. The CI-model based on TNM stage and IL6 level could better predict the OS, DFS, DMFS and lung-MFS of NPC patients. Here, the newly developed prognostic CI-model for predicting distant metastasis and death of NPC patients could facilitate patients consulting and individualized immunotherapy
Description:Date Completed 18.07.2016
Date Revised 08.04.2022
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2016.01.004